ASCO Annual Meeting: Renal Cell Carcinoma | Conference

Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC
June 25, 2021

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

Robert J. Motzer, MD, on Main HRQOL Takeaways From Phase 3 CLEAR Trial
June 17, 2021

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

Recommended Dose of Pembrolizumab Plus Cabozantinib Combo Induced Response in mRCC
June 09, 2021

The recommended phase 2 dose of pembrolizumab plus cabozantinib induced a response with a manageable safety profile for patients with mRCC.

Lenvatinib/Pembrolizumab Combo Improved Efficacy Over Sunitinib Across RCC Risk Groups
June 09, 2021

Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.

Adjusting for Subsequent Therapy Reveals Trend Toward OS Benefit With Lenvatinib Plus Everolimus in RCC
June 09, 2021

A post hoc analysis of the CLEAR trial shows that patients may derive an overall survival benefit with lenvatinib plus everolimus versus sunitinib for frontline treatment of RCC, with efficacy ongoing.

Long-Term Survival Benefit Reported for Pembrolizumab/Axitinib Combo in RCC
June 07, 2021

As frontline therapy, pembrolizumab plus axitinib led to a statistically significant survival benefit over standard-of-care therapy, according to data presented at the 2021 ASCO Annual Meeting.

HRQOL Analysis From CLEAR Trial Further Support Pembrolizumab/Lenvatinib Combo for Frontline RCC
June 07, 2021

Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.

Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC
June 05, 2021

CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.

Prolonged Duration of Response With Tivozanib for RCC Revealed at Long-Term Follow-Up
June 04, 2021

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.

DFS Benefit Noted With Adjuvant Pembrolizumab for Clear Cell RCC
June 04, 2021

Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.